# Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Study · id `cardio:ct-nct07037459` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07037459](<https://clinicaltrials.gov/study/NCT07037459>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07037459

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5056 participants.

## Technical summary

Registry record NCT07037459. Randomized; double masking; primary purpose treatment. Start 2025-06-25 (actual); primary completion 2028-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 5056 participants (planned count; ClinicalTrials.gov record NCT07037459, source copy `cardio:ctgov-nct07037459-2026-10-29`, retrieved 2026-10-31)
- Started: 2025-06-25 (actual) (ClinicalTrials.gov record NCT07037459, source copy `cardio:ctgov-nct07037459-2026-10-29`, retrieved 2026-10-31)
- Primary completion: 2028-06-30 (anticipated) (ClinicalTrials.gov record NCT07037459, source copy `cardio:ctgov-nct07037459-2026-10-29`, retrieved 2026-10-31)
- Completion: 2030-09-29 (anticipated) (ClinicalTrials.gov record NCT07037459, source copy `cardio:ctgov-nct07037459-2026-10-29`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Czechia; Denmark; Finland; France; Germany; Greece; Hong Kong SAR China; Hungary; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Puerto Rico; Romania; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT07037459, source copy `cardio:ctgov-nct07037459-2026-10-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07037459-2026-10-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Acronym: MARITIME-HF
- Condition: Heart Failure With Preserved Ejection Fraction
- Condition: Heart Failure With Mildly Reduced Ejection Fraction
- Condition: Obesity
- Intervention (Drug): Maridebart cafraglutide
- Intervention (Drug): Placebo
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition term reads as this condition, and the trial is coded with its broader condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: eedddb95a87e887467e61a930d9f2114d7b49992ea2f3006878938a8b08620fa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
